Debt-to-equity in % of Citius Pharmaceuticals, Inc. from Q2 2020 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Citius Pharmaceuticals, Inc. quarterly Debt-to-equity history and change rate from Q2 2020 to Q2 2025.
  • Citius Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 30 Jun 2025 was 81.3 %, a 505% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Citius Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2025 81.3 +67.9 +505% 30 Jun 2025
Q1 2025 57.9 +44.5 +333% 31 Mar 2025
Q4 2024 38.6 +25.2 +188% 31 Dec 2024
Q3 2024 23.8 +11.4 +91.1% 30 Sep 2024
Q2 2024 13.4 +1.77 +15.2% 30 Jun 2024
Q1 2024 13.4 +2.55 +23.6% 31 Mar 2024
Q4 2023 13.4 +3.91 +41.3% 31 Dec 2023
Q3 2023 12.5 +2.97 +31.3% 30 Sep 2023
Q2 2023 11.7 +2.95 +33.8% 30 Jun 2023
Q1 2023 10.8 +2.67 +32.8% 31 Mar 2023
Q4 2022 9.48 +1.6 +20.3% 31 Dec 2022
Q3 2022 9.49 30 Sep 2022
Q2 2022 8.72 30 Jun 2022
Q1 2022 8.13 31 Mar 2022
Q4 2021 7.88 31 Dec 2021
Q3 2020 25.7 30 Sep 2020
Q2 2020 26.8 30 Jun 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.